Insights

Expanding Market Presence Dermapharm's recent acquisition of herbal specialist Arkopharma and the expansion into consumer health markets across France, Spain, and Italy highlight its growth strategy. This provides sales opportunities by offering healthcare products tailored to diverse European markets and developing cross-border distribution partnerships.

Diverse Product Portfolio With approximately 1,300 marketing authorizations spanning pharmaceuticals, medical devices, and food supplements, Dermapharm presents a wide-ranging portfolio that can be leveraged for upselling and bundling opportunities within its existing customer base, especially in therapeutic areas where the company is a market leader.

International R&D Focus Dermapharm's commitment to R&D and strategic acquisitions supports its innovation pipeline, creating opportunities to introduce new formulations and branded products to healthcare providers and distributors, especially in markets where the company is strengthening its presence.

Herbal and Plant-Based Products The company's expertise in herbal extracts through Euromed and synthetic cannabinoids from C³ Group opens doors for sales in natural health segments, nutraceuticals, and cosmetics, appealing to consumers seeking plant-based and herbal solutions.

Growing Consumer Health Segment With a strategic focus on expanding its consumer health footprint in Europe, Dermapharm offers potential sales opportunities in over-the-counter products, food supplements, and wellness offerings, driven by its recent acquisitions and localized market strategies.

Dermapharm Holding SE Tech Stack

Dermapharm Holding SE uses 3 technology products and services including Contao, Piwik, Google Analytics, and more. Explore Dermapharm Holding SE's tech stack below.

  • Contao
    Content Management System
  • Piwik
    System Analytics & Monitoring
  • Google Analytics
    Web Analytics

Dermapharm Holding SE's Email Address Formats

Dermapharm Holding SE uses at least 1 format(s):
Dermapharm Holding SE Email FormatsExamplePercentage
First.Last@dermapharm.deJohn.Doe@dermapharm.de
50%
First.Last@dermapharm.deJohn.Doe@dermapharm.de
50%

Frequently Asked Questions

What is Dermapharm Holding SE's official website and social media links?

Minus sign iconPlus sign icon
Dermapharm Holding SE's official website is dermapharm.de and has social profiles on LinkedIn.

How much revenue does Dermapharm Holding SE generate?

Minus sign iconPlus sign icon
As of December 2025, Dermapharm Holding SE's annual revenue is estimated to be $1.2B.

What is Dermapharm Holding SE's NAICS code?

Minus sign iconPlus sign icon
Dermapharm Holding SE's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Dermapharm Holding SE have currently?

Minus sign iconPlus sign icon
As of December 2025, Dermapharm Holding SE has approximately 1K employees across 3 continents, including EuropeAfricaOceania. Key team members include Cmo, Vorstand Marketing & Vertrieb: A. E.Cfo/ Cco: C. D.Head Of Investor Relations & Corporate Communications: B. H.. Explore Dermapharm Holding SE's employee directory with LeadIQ.

What industry does Dermapharm Holding SE belong to?

Minus sign iconPlus sign icon
Dermapharm Holding SE operates in the Pharmaceutical Manufacturing industry.

What technology does Dermapharm Holding SE use?

Minus sign iconPlus sign icon
Dermapharm Holding SE's tech stack includes ContaoPiwikGoogle Analytics.

What is Dermapharm Holding SE's email format?

Minus sign iconPlus sign icon
Dermapharm Holding SE's email format typically follows the pattern of First.Last@dermapharm.de. Find more Dermapharm Holding SE email formats with LeadIQ.

When was Dermapharm Holding SE founded?

Minus sign iconPlus sign icon
Dermapharm Holding SE was founded in 1991.

Dermapharm Holding SE

Pharmaceutical ManufacturingBavaria, Germany1001-5000 Employees

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand-name products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.

In the "Branded pharmaceuticals and other healthcare products" segment, Dermapharm has approximately 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.

In the "Herbal extracts" segment, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries. At the beginning of 2022, the segment was expanded to include Germany-based C³ Group, which develops, manufactures and markets synthetic cannabinoids. C³ Group is the market leader for dronabinol in Germany and Austria.

Dermapharm's business model also includes the "Parallel import business" segment that operates under the "axicorp" brand. Based on revenue, axicorp was among the top five parallel import companies in Germany in 2021.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, Dermapharm has continuously optimised its business over the past 30 years and sought external growth opportunities in addition to organic growth. Dermapharm is firmly committed to continuing on this profitable growth course in the future.

Section iconCompany Overview

NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
1991
Employees
1001-5000

Section iconFunding & Financials

  • $1M$10M

    Dermapharm Holding SE's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Dermapharm Holding SE's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.